OBJECTIVE: Homocystinemia is an important independent risk factor for atherosclerosis. Inflammatory cytokines play key roles in the development of atherogenesis. This study investigated the effect of homocysteine on inflammatory cytokine expression. METHODS: Human monocytes were treated in vitro with a variety of DL-homocysteine concentrations that ranged from physiologic concentration to higher than pathophysiologic concentration, and we analyzed their expressions of inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, interleukin-8, interleukin-12, and migration inhibitory factor. RESULTS: DL-homocysteine at a marginal physiologic concentration of 2 microg/mL (15 microM) activated monocytes. In addition, DL-homocysteine at the pathophysiologic dose of 25 microg/mL (185 microM) induced mRNA and protein expressions of inflammatory cytokines tumor necrosis factor-alpha, IL-1beta, interleukin-6, interleukin-8, and interleukin-12. Moreover, at the larger dose of 50 microg/mL (370 microM) DL-homocysteine decreased expression of migration inhibitory factor at the mRNA and protein levels. CONCLUSION: These findings suggest that homocysteine may contribute to the initiation and progression of vascular disease by activating monocytes, resulting in the secretion of cytokines that amplify the inflammatory response.
OBJECTIVE:Homocystinemia is an important independent risk factor for atherosclerosis. Inflammatory cytokines play key roles in the development of atherogenesis. This study investigated the effect of homocysteine on inflammatory cytokine expression. METHODS:Human monocytes were treated in vitro with a variety of DL-homocysteine concentrations that ranged from physiologic concentration to higher than pathophysiologic concentration, and we analyzed their expressions of inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, interleukin-8, interleukin-12, and migration inhibitory factor. RESULTS:DL-homocysteine at a marginal physiologic concentration of 2 microg/mL (15 microM) activated monocytes. In addition, DL-homocysteine at the pathophysiologic dose of 25 microg/mL (185 microM) induced mRNA and protein expressions of inflammatory cytokines tumor necrosis factor-alpha, IL-1beta, interleukin-6, interleukin-8, and interleukin-12. Moreover, at the larger dose of 50 microg/mL (370 microM) DL-homocysteine decreased expression of migration inhibitory factor at the mRNA and protein levels. CONCLUSION: These findings suggest that homocysteine may contribute to the initiation and progression of vascular disease by activating monocytes, resulting in the secretion of cytokines that amplify the inflammatory response.
Authors: Amy K Keating; Cynthia Freehauf; Hua Jiang; Gary L Brodsky; Sally P Stabler; Robert H Allen; Douglas K Graham; Janet A Thomas; Johan L K Van Hove; Kenneth N Maclean Journal: Mol Genet Metab Date: 2011-05-05 Impact factor: 4.797
Authors: Chan Woo Park; Ae Ra Han; Joanne Kwak-Kim; So Yeon Park; Jung Yeol Han; Mi Kyoung Koong; In Ok Song; Kwang Moon Yang Journal: Clin Exp Reprod Med Date: 2011-09-30
Authors: Aline A da Cunha; Andréa G K Ferreira; Samanta O Loureiro; Maira J da Cunha; Felipe Schmitz; Carlos Alexandre Netto; Angela T S Wyse Journal: Neurochem Res Date: 2012-04-08 Impact factor: 3.996
Authors: Ann Van Campenhout; Corey S Moran; Adam Parr; Paula Clancy; Catherine Rush; Hieronim Jakubowski; Jonathan Golledge Journal: Atherosclerosis Date: 2008-05-28 Impact factor: 5.162